National Academies Join Call For More Diversity In Trials

A new report from the National Academies of Sciences, Engineering, and Medicine issued a new report on the urgent need for better representation of underrepresented populations in clinical trials and research.

Diversity (Lightspring/Shutterstock.com)
• Source: Shutterstock (Shutterstock)

The National Academies of Sciences, Engineering, and Medicine (NASEM) is pushing the US government – including the US Food and Drug Administration and National Institutes of Health – to do more to improve the representation of underrepresented populations in clinical trials.

With the support from the National Institutes of Health, NASEM produced a new report recommending “system-level actions” for improving diversity in clinical trials. The report was written by NASEM’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

More from ESG